For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Medimmune Limited

USPTO Granted Patents = 541

CIPO Patents = 49

EPO Patents = 221

Trademarks = 7

Forward Citations = 5,697

Loading Chart...

Loading Chart...

761 inventors (with patents filed for the assignee):

Philip Wilson Howard (64 out of 92 patents)

George William Kemble (38 out of 41 patents)

Herren Wu (32 out of 50 patents)

4. Leslie Sydnor Johnson (32 out of 125 patents)

5. Changshou Gao (30 out of 32 patents)

6. Ralph Raymond Minter (29 out of 31 patents)

7. Patricius Hendrikus Cornelis Van Berkel (21 out of 24 patents)

8. Hong Jin (21 out of 24 patents)

9. William Dall'Acqua (20 out of 21 patents)

10. Melissa Marie Damschroder (20 out of 25 patents)

11. Scott Koenig (19 out of 56 patents)

12. Chin-Fen Yang (19 out of 19 patents)

13. Partha S Chowdhury (18 out of 30 patents)

14. Scott A Hammond (16 out of 16 patents)

15. Nicole Kallewaard-LeLay (16 out of 18 patents)

Core Competencies:

Protein Disulfide Bonds

Combination Therapies

Anti-Pseudomonas Antibodies

Cancer Treatment

Influenza Antibodies

Azetidobenzodiazepine Conjugates

Neurodegenerative Diseases

Bispecific Binding Proteins

Monoclonal Antibody-Drug Conjugates

Thymic Stromal Lymphopoietin

Engineered O-Glycosylation

Therapeutic Binding Molecules

541 patents: Sort by Forward Citations

1. 12466874 - Prevention of protein disulfide bond reduction (2025-11-11),

2. 12428473 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2025-09-30),

3. 12391768 - Antibodies to ticagrelor and methods of use (2025-08-19),

4. 12371464 - Polypeptides and uses thereof (2025-07-29),

5. 12357692 - Method of treating influenza A (2025-07-15),

6. 12344664 - Antibodies to amyloid beta (2025-07-01),

7. 12325740 - Neutralizing anti-influenza B antibodies and uses thereof (2025-06-10),

8. 12312397 - Anti-O2 antibodies and uses thereof (2025-05-27),

9. 12264194 - Decreasinginfections in colonized patients (2025-04-01),

10. 12224043 - Methods for determining treatment for cancer patients (2025-02-11),

11. 12209126 - Treatment of cancer (2025-01-28),

12. 12209099 - Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer (2025-01-28),

13. 12187788 - Methods for treating atopic dermatitis and related disorders (2025-01-07),

14. 12187774 - Heterodimeric Relaxin fusions and uses thereof (2025-01-07),

15. 12178911 - Dry powder formulations of thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of use thereof (2024-12-31),

MedImmune Limited is a leading biotechnology company specializing in the research, development, and production of innovative biotherapeutic drugs. With a focus on harnessing the power of the immune system, MedImmune aims to improve the health and wellbeing of individuals worldwide. The company operates with the mission of transforming scientific discoveries into valuable medicines that address unmet medical needs. MedImmune is committed to advancing science and collaborating with partners in academia, government, and industry to drive innovation in the field of biotechnology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

541 Patents

#2 in Cambridge

#30 in United Kingdom

#1,743 in the World

Cambridge, United Kingdom

Medimmune Limited

Forward Citations = 5,697

761 inventors:

Philip Wilson Howard (64 out of 92 patents)

George William Kemble (38 out of 41 patents)

Herren Wu (32 out of 50 patents)

4. Leslie Sydnor Johnson (32 out of 125 patents)

5. Changshou Gao (30 out of 32 patents)

Please report any incorrect information to support@idiyas.com

Loading…